Fig. 3.

FMC increases LXRα activity via deacetylation. FMC (0% FBS, 24 h) in BRECs (a) decreases levels of non-active, deacetylated LXRα; and (b) increases total LXRα protein levels, quantification shown in (c). The data for active LXR quantified by subtracting acetylated LXRα in (a) from total LXRα in (b) is presented in (d) as mean ± SEM. BRECs were treated with SRT1720 (1 μmol/l) and/or infected with constitutively acetylated LXRα (Q432) for 24 h. Expression of Lxrα (e) or SIRT1-dependent activation of LXRα (f) presented as SRT1720-induced increase in Abca1 expression in BRECs (Ctl) and BRECs infected with Q432. Ratios determined from three independent experiments,*p<0.05, **p<0.01, ***p<0.001. Data are represented as mean ± SEM. Ctl, control; IB, immunoblot; IP, immunoprecipitation